ESR1 and breast carcinoma: The PI3K/Akt signaling pathway, in particular, is an important target in ER+ breast cancer as PI3K deregulation through mutation of the catalytic subunit alfa of PI3K (PIK3CA) is a common occurrence in breast cancer and correlates with the ER+ status [85].